Gross margin and R&D intensity: benchmarking pharma profitability

Why business model determines the "right" margin

Pharma is not one industry for financial purposes. It's at least three:

• Branded biopharma: sells patent-protected drugs, prices set on clinical value, low unit manufacturing cost relative to price.
• Generics: sells off-patent molecules, prices set by competition, often many manufacturers of the same drug.
• CDMO: doesn't own drugs at all, sells manufacturing and development services to other pharma companies, priced more like industrial services.

Because revenue comes from different sources (patent-protected pricing power vs. commodity manufacturing vs. fee-for-service), the "normal" ratios differ enormously. Benchmarking one against another without adjusting for model is a common analyst mistake.

The three ratios, defined

Gross marginGross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → = (Revenue − Cost of Goods Sold, COGS) ÷ Revenue.

COGS in pharma mainly means active ingredient costs, manufacturing, and quality control, not R&D.

R&D-to-sales ratio = R&D expense ÷ Revenue.

Measures how much of every sales dollar gets reinvested into the drug pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → (the portfolio of drug candidates in development).

SG&A intensity = Selling, General & Administrative expense ÷ Revenue.

Covers sales force costs, marketing, legal, and corporate overhead.

Together these three ratios reveal where a company's money actually goes: production, innovation, or commercialization and admin.

Worked calculation: same $1 of revenue, three business models

Assume each company earns $1,000 million in revenue. These figures are illustrative, built from typical industry patterns, not any single real company's actuals.

| Line | Branded biopharma | Generics maker | CDMO |

|---|---|---|---|

| Revenue | 1,000 | 1,000 | 1,000 |

| COGS | 150 | 620 | 750 |

| Gross profit | 850 | 380 | 250 |

| Gross marginGross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → | 85% | 38% | 25% |

| R&D expense | 250 | 50 | 40 |

| R&D-to-sales | 25% | 5% | 4% |

| SG&A expense | 300 | 150 | 80 |

| SG&A intensity | 30% | 15% | 8% |

| Operating profit (approx.) | 300 | 180 | 130 |

| Operating margin | 30% | 18% | 13% |

Calculation for branded biopharma gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète →: (1,000 − 150) ÷ 1,000 = 0.85, or 85%.

Calculation for CDMO R&D-to-sales: 40 ÷ 1,000 = 0.04, or 4%.

Notice: the CDMO has the lowest gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → and lowest operating margin, but that's structurally normal, it's a services and manufacturing business, not a low-quality one. The generics maker sits in between. The branded biopharma looks best on every ratio, but it's also carrying the highest R&D risk: most drug candidates fail in clinical trials, so that 25% R&D spend is a bet on a handful of successes funding many failures.

Real-world benchmark ranges (as of 2025/2026, estimates)

These are approximate ranges compiled from public company filings and industry commentary, treat as directional, not precise:

• Large branded biopharma (e.g., companies like Merck, AbbVie, Novartis, Roche): gross margins commonly 75% to 88%; R&D-to-sales typically 15% to 25%, though some smaller innovators run 40%+ pre-commercialization. Source benchmark context: Aswath Damodaran's margin data by industry sector, updated annually, useful free reference for cross-sector comparison.
• Generics makers (e.g., Teva, Viatris, Sandoz, Sun Pharma): gross margins often 35% to 55%; R&D-to-sales typically 3% to 8%, since most spend goes to bioequivalence studies (proving a generic behaves the same as the original drug), not novel discovery.
• CDMOs (e.g., Lonza, Catalent prior to its 2024 acquisition, Samsung Biologics): gross margins often 20% to 35%; R&D-to-sales usually under 5%, since R&D here means process development, not drug discovery.

US vs. Europe nuance: European branded biopharma majors (Novartis, Roche, Sanofi) report broadly similar gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → ranges to US peers, but SG&A intensity is often a few points lower, partly because European pricing and marketing environments (more government-negotiated pricing, less direct-to-consumer advertising, which is largely banned in the EU outside limited cases) require smaller commercial sales forces than the US market.

What moves each ratio (and what to check)

Gross margin drops when:

• A branded drug loses patent protection and faces generic competition (a "patent cliff")
• Manufacturing shifts to more complex modalities (biologics, cell and gene therapy) with higher production cost per unit
• Government price controls compress net price without a matching cost cut (relevant in Europe's reference-pricing systems and increasingly in the US under the Inflation Reduction Act's Medicare drug price negotiation provisions)

R&D-to-sales rises when:

• A company is pre-revenue or early-commercial and spending heavily on trials relative to a small sales base (common at biotech firms before their first approved drug)
• A company is defending its pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → against upcoming patent expirations

SG&A intensity rises when:

• A company is launching a new drug and building a specialist sales force
• A company operates across many small national markets in Europe, each requiring separate reimbursement negotiations and local market access teams

Reading the ratios together, not alone

No single ratio tells the story. A biotech with 90% gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → and 60% R&D-to-sales isn't necessarily healthy, it may be burning cash with no approved product yet (common for clinical-stage companies with no marketed drug). A generics maker with 45% gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → but falling R&D spend may be milking an aging portfolio rather than renewing it.

A quick diagnostic sequence:

1. Check gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → first: does it match the business model (branded, generic, CDMO)?

2. Check R&D-to-sales: is spend proportionate to pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → stage and patent cliff exposure?

3. Check SG&A intensity: is commercial spend scaling with revenue, or growing faster (a red flag for overspend relative to sales traction)?

4. Only then look at operating margin, the ratio that nets all three effects together.

🎬 [VIDEO: "How Big Pharma Makes Money" - youtube.com/@CNBC - a concise explainer on pharma revenue models, patent economics, and where margins come from, useful for building intuition before diving into filings.]

A note on data sources

For real company numbers, use 10-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète → and 10-Q filings for US-listed companies (available free via SEC EDGAR) and annual reports for European companies (available via each company's investor relations site, or via national registries like the UK's Companies House for London-listed firms). Always check whether a reported "gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète →" excludes or includes items like amortization of acquired intangible assets, this can shift the number by several points and analysts sometimes report both a GAAP and a non-GAAP (adjusted) version.

Key Takeaways

• Gross marginGross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète →, R&D-to-sales, and SG&A intensity must be benchmarked against business model, not across the whole "pharma industry" as if it were homogeneous.
• Rough 2025/2026 estimate ranges: branded biopharma gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → 75-88%, generics 35-55%, CDMO 20-35%; R&D-to-sales roughly 15-25% for branded innovators versus 3-8% for generics.
• Worked example: gross margin = (Revenue − COGS) ÷ Revenue; a company with $1,000 million revenue and $150 million COGS has an 85% .